This is a working overview of Somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-13 and is reviewed periodically as new material appears.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
the Emil Fischer Medal of the Society of German Chemists (1922), the Cannizaro Prize of the Royal Academy of Science in Rome (1938), the Copernicus Prize of the University of Konigsberg (1941), the Gothenius Medal of the Akademie der Naturforscher (1943), the Max Planck Medal of the German Physical Society, with Lise Meitner (1949), the Goethe Medal of the city of Frankfurt-on-the-Main (1949), the Golden Paracelsus Medal of the Swiss Chemical Society (1953), the Faraday Lectureship Prize with Medal from the Royal Society of Chemistry (1956), the Grotius Medal of the Hugo Grotius Foundation (1956), the Wilhelm Exner Medal of the Austrian Industry Association (1958), the Helmholtz Medal of the Berlin-Brandenburg Academy of Sciences and Humanities (1959), and the Harnack medal in Gold from the Max Planck Society (1959).
== Efforts to characterize all human cell types == Several efforts have been made to make a list or a map of all human cells. One of the largest and most recent is the HuBMAP (Human BioMolecular Atlas Program). The HuBMAP project has organized 1551 different samples in 17 collections, each dedicated to a different system. However, this project still only mapped about 31 of the human body's 70 organs. Their datasets and visualisations place great emphasis on biomarkers and location in the body, but less on cell development and how cells can change over time. Usually specific surface proteins are used to identify cells, and based on this they are put into different categories. Another major effort to make an overview of these proteins that allows us to observe cell types is the Human Protein Atlas. A similar project, the Human Brain Project has also attempted to map the human brain, although much of the publicly accessible model does not have cellular resolution.
=== Weekly frequency === In general, more weekly training sessions lead to higher increases in physical strength. However, when training volume was equalized, training frequency had no influence on muscular strength. In addition, greater frequency had no significant effect on single-joint exercises. There may be a fatigue recovery effect in which spreading the same amount of training over multiple days boosts strength gains, but this has to be confirmed by future studies. For muscle growth, a training frequency of two sessions per week had greater effects than once per week. Whether training a muscle group three times per week is superior to a twice-per-week protocol remains to be determined.
In Buddhism, the Dharma Chakra is widely used to represent the Buddha's Dharma (Buddha's teaching and the universal moral order), Gautama Buddha himself and the walking of the path to enlightenment, since the time of Early Buddhism. The symbol is also sometimes connected to the Four Noble Truths, the Noble Eightfold Path and Dependent Origination. The pre-Buddhist dharmachakra (Pali: dhammacakka) is considered one of the ashtamangala (auspicious signs) in Hinduism and Buddhism and often used as a symbol of both faiths. It is one of the oldest known Indian symbols found in Indian art, appearing with the first surviving post-Indus Valley Civilisation Indian iconography in the time of the Buddhist king Ashoka. The Buddha is said to have set the "wheel of dharma" in motion when he delivered his first sermon, which is described in the Dhammacakkappavattana Sutta. This "turning of the wheel" signifies a great and revolutionary change with universal consequences, brought about by an exceptional human being. Buddhism adopted the wheel as a symbol from the Indian mythical idea of the ideal king, called a chakravartin ("wheel-turner", or "universal monarch"), who was said to possess several mythical objects, including the ratana cakka (the ideal wheel). The Mahā Sudassana Sutta of the Digha Nikaya describes this wheel as having a nave (nābhi), a thousand spokes (sahassārāni) and a felly (nemi), all of which are perfect in every respect.
Sources: en.wikipedia.org
However, Lorraine Berry of The Boston Globe criticizes the novel as poverty porn, arguing that, In seeking to raise awareness of child hunger and poverty in the United States, Kingsolver turns her characters’ lives into tales of misery and the inevitability of failure. Her characters wallow in dark hollows with little light, condemned to forever repeat the horrific mistakes of previous generations. She makes the people of Appalachia into objects of pity, but in doing so, also intimates that falling into drug abuse, rejecting education, and 'clinging' to their ways are moral choices.
=== Software packages === As described by Andreotti et al. in 2012, Antilope is a combination of Lagrangian relaxation and an adaptation of Yen's k shortest paths. It is based on 'spectrum graph' method and contains different scoring functions, and can be comparable on the running time and accuracy to "the popular state-of-the-art programs" PepNovo and NovoHMM. Grossmann et al. presented AUDENS in 2005 as an automated de novo peptide sequencing tool containing a preprocessing module that can recognize signal peaks and noise peaks. Lutefisk can solve de novo sequencing from CID mass spectra. In this algorithm, significant ions are first found, then determine the N- and C-terminal evidence list. Based on the sequence list, it generates complete sequences in spectra and scores them with the experimental spectrum. However, the result may include several sequence candidates that have only little difference, so it is hard to find the right peptide sequence. A second program, CIDentify, which is a modified version by Alex Taylor of Bill Pearson's FASTA algorithm, can be applied to distinguish those uncertain similar candidates. Mo et al. presented the MSNovo algorithm in 2007 and proved that it performed "better than existing de novo tools on multiple data sets". This algorithm can do de novo sequencing interpretation of LCQ, LTQ mass spectrometers and of singly, doubly, triply charged ions. Different from other algorithms, it applied a novel scoring function and use a mass array instead of a spectrum graph. Fisher et al. proposed the NovoHMM method of de novo sequencing.
=== Long-term use === Long-term use of PPIs is strongly associated with the development of benign polyps from fundic glands (which is distinct from fundic gland polyposis); these polyps do not cause cancer and resolve when PPIs are discontinued. No association is seen between PPI use and cancer, but use of PPIs may mask gastric cancers or other serious gastric problems. There is a possible association between long-term use and dementia which requires further study to confirm. An article published in 2013 claims that the long-term use of PPIs is associated with decreased calcium absorption (causing increased risk of osteoporosis and fractures), decreased magnesium absorption (causing electrolyte disturbances), and increased risk of certain infections, such as C. difficile and community-acquired pneumonia. The authors hypothesize that this is due to decreased stomach acid production.
Sources: en.wikipedia.org
In order to better assess radiation protection, the number of X-ray examinations, including the dose, has been recorded annually in Germany since 2007. However, the Federal Statistical Office does not have complete data for conventional X-ray examinations. In 2014, the total number of X-ray examinations in Germany was estimated to be about 135 million, of which about 55 million were dental X-ray examinations. The average effective dose from x-ray examinations per inhabitant in Germany in 2014 was about 1.55 mSv (about 1.7 x-ray examinations per inhabitant per year). The proportion of dental X-rays is 41%, but accounts for only 0.4% of the collective effective dose. In Germany, Section 28 of the X-ray Ordinance (RöV) has required since 2002 that the attending physician must have an X-ray pass available for X-ray examinations and offer it to the patient. The pass contains information about the patient's X-rays to avoid unnecessary examinations and to allow comparison with previous images. With the entry into force of the new Radiation Protection Ordinance on December 31, 2018, this obligation no longer applies. In Austria and Switzerland, x-ray passports have so far been available voluntarily. In principle, there must always be both a justifiable indication for the use of X-rays and the informed consent of the patient. In the context of medical treatment, informed consent refers to the patient's agreement to all types of interventions and other medical measures. § 630d Act of (in German)
2000: Feodor Lynen Fellowship of the Alexander von Humboldt Foundation 2002: Emmy Noether Fellowship of the German Research Foundation (DFG) 2002: Friedrich Weygand Prize of the Max Bergmann Circle e.V. 2003: Young Scientist Award for Natural Product Research of DECHEMA e.V. 2003: Eli Lilly Lecture Award 2006: Lecturer Fellowship from the German Chemical Industry Association (VCI) 2010: Sigma Aldrich Lecture, Lunteren, Netherlands 2013: Visiting Professorship at Ben Gurion University of the Negev, Israel 2014: Van Arkel Chair at Leiden University, Netherlands 2020: Recipient of the Max Bergmann Medal for outstanding achievements in the field of peptide natural products
== Side effects == Adverse effects of hydromorphone are similar to those of other potent opioid analgesics such as morphine and heroin. The major hazards of hydromorphone include dose-related respiratory depression, urinary retention, bronchospasm, and sometimes, circulatory depression. More common side effects include lightheadedness, dizziness, nystagmus, sedation, itching, constipation, nausea, vomiting, headache, perspiration, and hallucinations. These symptoms are common in ambulatory patients and in those not experiencing severe pain. Simultaneous use of hydromorphone with other opioids, muscle relaxants, tranquilizers, sedatives, and general anesthetics may significantly depress respiration, progressing to coma or death. Taking benzodiazepines (e.g., diazepam) in conjunction with hydromorphone may increase side effects such as dizziness and difficulty concentrating. If simultaneous use of these drugs is required, dose adjustment may be made. A particular problem that may occur with hydromorphone is accidental administration in place of morphine due to a mix-up between the similar names, either at the time the prescription is written or when the drug is dispensed. This has led to several deaths and calls for hydromorphone to be distributed in distinctly different packaging from morphine to avoid confusion. Massive overdoses are rarely observed in opioid-tolerant individuals, but when they occur, they may lead to circulatory system collapse.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。